ASH 2017 | Novel ALL treatment strategies: CAR T-cells
Elias Jabbour
CAR T-cells are a universally exciting area in hematological oncology. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the landscape of CAR T-cell therapy for acute lymphoblastic leukemia (ALL). He covers the approval of the CAR T-cell product tisagenlecleucel for pediatric and adolescent ALL based on data from the Phase II ELIANA trial (NCT02435849). Dr Jabbour also discusses the landscape of this field moving forwards, including the potentially game-changing use of off-the-shelf allogeneic CAR T-cell therapy.
Related videos
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
An exciting era for CAR T-cell therapy
Mohamad Mohty
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Talha Munir
